Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters

Cross-sectional study

Aurelija Noreikaité, Master of pharmacy, PhD studenta,∗, Franck Saint-Marcoux, MD, PhDbc,d, Pierre Marquet, MD, PhDbc,d, Edmundas Kadaševičius, MD, PhDa, Edgaras Stankevičius, MD, PhDa

Abstract
The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR).

Anonymized medical records of 404 kidney recipients were reviewed. The main MPA pharmacokinetic parameters (AUC_{0-12}) and C_{\text{max}} were evaluated.

The patients treated with a higher mean dose of CsA displayed higher MPA AUC_{0-12} exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h·mg/L; r_s = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h·mg/L; r_s = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h·mg/L; r_s = 0.608, P < 0.05).

A positive correlation was also observed between the mean CsA dose and the MPA C_{\text{max}} in the low-dose MMF group (C_{\text{max}} 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; r_s = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.62 mg/L; r_s = 0.414, P < 0.01).

The comparative analysis between 2 treatment arms (MMF + CsA and MMF + EVR) showed that MPA AUC_{0-12} exposure was by 43% higher in the patients treated with a medium dose of MMF and EVR than in the patients treated with a medium dose of MMF and CsA.

The data of the present study suggest a possible CsA versus EVR influence on MPP pharmacokinetics. Study results show that CsA has an impact on the main MPA pharmacokinetic parameters (AUC_{0-12} and C_{\text{max}}) in a CsA dose-related manner, while EVR mildly influence or does not affect MPA pharmacokinetic parameters. Low-dose CsA (lower than 180 mg/day) reduces MPA AUC_{0-12} exposure under the therapeutic window and may lead to ineffective therapy, while a high-dose CsA (>240 mg/day) is related to greater than 10 mg/L MPA C_{\text{max}} and increases the likelihood of adverse events.

Abbreviations: AUC = area under the concentration time curve, C_{\text{max}} = maximal concentration, CNI = calcineurin inhibitor, CS = corticosteroid, CsA = cyclosporine, EVR = everolimus, MPP = mycophenolate mofetil, MPA = mycophenolic acid, MPAG = 7-O-glucuronide conjugate, MRP2 = multidrug resistance-associated protein 2, mTOR = mammalian target of rapamycin, Pgp = P-glycoprotein.

Keywords: cyclosporine, drug-to-drug interaction, mycophenolate mofetil, pharmacokinetics, renal transplantation

1. Introduction
Immunosuppressive drugs are characterized by high variability in metabolism and pharmacokinetics that may result in drug toxicity or lack of efficacy.[1,3] Chronic maintenance immunosuppression in transplantation requires special attention especially to the right dosage selection based on the assessment of plasma drug concentration. Low immunosuppressant concentration in plasma increases the risk of transplant rejection in the acute posttransplant period,[2,3] while increased drug exposure may lead to the higher risk of adverse drug reactions,[4,5] especially chronic allograft nephropathy.

The National Institute for Health and Care Excellence has outlined the recommendations for patients receiving kidney transplant.[6] Basiliximab or daclizumab with or without cyclosporine (CsA) are recommended as an option for induction therapy. The National Institute for Health and Care Excellence has also noted that mycophenolate mofetil (MMF) should be used as an option as part of an immunosuppressive regimen only when intolerance to calcineurin inhibitors (CNIs), particularly nephrotoxicity leading to risk of chronic allograft dysfunction, is proven or in situations with a high risk of nephrotoxicity necessitating minimization or avoidance of a CNI.[6] Meanwhile, the Kidney Disease Improving Global Outcomes Clinical Practice Guidelines recommend using a combination of a CNI and an antiproliferative agent with or without corticosteroids (CSs).[7] However, in clinical
practice, triple therapy with a CNI (CsA); an antiproliferative agent (azathioprine or MMF); and a CS has been customarily constituted. Later on, many new regimens have been developed that incorporate rapid glucocorticoid elimination, CNI dose reduction or elimination due to numerous potential glucocorticoid, and CNI toxicities. CNI withdrawal has been attempted by conversion to less nephrotoxic mammalian target of rapamycin (mTOR) inhibitors.[4–10] The MANDELA study (NCT00862979) initiated in 2009 was also designed to assess the benefit of either CNI-free or CNI-minimized everolimus (EVR)-based regimen.[11]

MMF is one of the components of triple therapy and an integral component of toxicity-sparing regimens that seek to minimize exposure to the nephrotoxic CNI.[12] Recently, the need for guidelines on MMF dosing has increased as more individualized immunosuppressive drug regimens are used.[13] However, MMF is of possible concern and its combination with drugs, environmental pollutants, or food constituents, which activate cytochrome P450 transcriptional factor, may represent a significant toxicological risk.[14] An important detail related to the immunosuppressive regimen is that CsA used together with MMF inhibits the enteroleptic (re)circulation of mycophenolic acid (MPA), an active metabolite, and its inactive metabolite 7-O-glucuronic conjugate (MPAG) and results in significantly lower dose-corrected MPA concentrations in CsA-treated patients, which in turn will lead to early clinical MPA area under the concentration time curve (AUC) under exposure in 50%.[15] The need to double the dose of MMF in case of CsA co-administration to achieve the same MPA levels have been emphasized,[16] but is not always followed (usually in clinical practice the dose of MMF in co-administration of CsA is 2 g/day).

Genetic polymorphisms also play an important role. P-glycoprotein (Pgp) and cytochrome P450 3A4 have been recognized as determinants of the bioavailability of widely used immunosuppressants such as CsA, tacrolimus, and sirolimus. These immunosuppressants act as substrates and/or inhibitors of Pgp, alter the bioavailability of many concomitantly used drugs, and are potential inducers of drug–drug interactions.[17]

EVR, a derivative of sirolimus, is used in solid–organ transplantation and offers immunosuppression without CNI-induced toxicities.[18,19] EVR in combination with MMF has shown promising renal outcomes after liver, heart, and kidney transplantation.[20–22] Moreover, mTOR inhibitors have been shown to prevent tumors and even to reduce metastatic tumor growth by angiogenesis.[23] Meanwhile, the combination of EVR and MMF used for immunosuppression has shown dose-dependent antiproliferative effects in tumor cell lines in vitro,[24] and this is an additional benefit for the immunosuppression regimen, which in general poses a greater risk of cancer.[25,26] These results strengthen the possibility of equilibrium between efficient immunosuppressive drug therapy and preservation over the development of cancer,[23,26] thereby offering new therapeutic strategies for the treatment of malignancies in clinical practice.[27,28] However, drug–drug interaction between these drugs might exist as well, and studies on the influence of EVR on MPA pharmacokinetic parameters are limited and it requires further evaluation.

The objective of the present study was to assess the influence of CsA on the main MPA pharmacokinetic parameters and to compare the effect of CsA and EVR on the main MPA pharmacokinetic parameters in patients with a renal graft.

Table 1

| Characteristic of the study groups. | Low-dose MMF group (1000 mg/day) | Medium-dose MMF group (2000 mg/day) | High-dose MMF group (3000 mg/day) |
|-----------------------------------|-------------------------------|----------------------------------|----------------------------------|
| **Cyclosporine group** (n = 83)   |                               |                                  |                                  |
| No of patients                    | 19                            | 50                               | 14                               |
| Age, mean ± SD (range), years     | 56.7 ± 10.3 (35–70)            | 54.0 ± 12.1 (25–75)              | 57.1 ± 8.5 (48–72)               |
| CsA dose, mean ± SD (range), mg/day | 171.58 ± 26.72* (120–200)   | 204.80 ± 46.26 (120–300)        | 245.71 ± 59.60 (150–300)         |
| CsA C0, mean ± SD (range), µg/L   | 121.05 ± 57.10 (53.00–208.00) | 118.70 ± 46.98 (59.00–254.00)   | 195.36 ± 191.28 (91.00–843.00)  |
| Posttransplant period, mean ± SD (range), years | 10.13 ± 7.93 (1.00–26.24) | 6.26 ± 3.70 (0.26–14.94)* | 1.69 ± 2.51 (0.02–8.63)* |
| **EVR group** (n = 17)            |                               |                                  |                                  |
| No of patients                    | 9                             | 4                                | 4                                |
| Age, mean ± SD (range), years     | 68.0 ± 8.4 (51–77)             | 58.0 ± 10.8 (50–74)              | 70.2 ± 1.4 (69–72)               |
| EVR dose, range, mg/day           | 2–5                           | 2–5                              | 2–5                              |
| ECR C0, range, µg/L               | 5–15                          | 5–15                             | 5–15                             |
| Posttransplant period, mean ± SD (range), years | 1.47 ± 1.33 (0.32–3.94)* | 3.43 ± 1.55 (1.59–5.26) | 0.17 ± 0.11 (0.07–0.27)* |

* C0 = trough level, CsA = cyclosporine, EVR = everolimus, MMF = mycophenolate mofetil, SD = standard deviation.

1 Four patients early posttransplants (3 months–1 year) versus 46 patients posttransplantation time >1 year.
2 Three patients (<30 days), 2 patients (30 days–3 months), 4 patients (3 months–1 year), and 5 patients (>1 year).
3 Four patients (3 months–1 year).
4 All are early posttransplants.
According to the MMF daily dose, the study patients were allocated into the 3 study groups: the low MMF dose group received 1000 mg/day (28 patients); medium MMF dose group, 2000 mg/day (54 patients); and high MMF dose group, 3000 mg/day (18 patients).

A CsA daily dose varied from 120 to 300 mg. CsA pharmacokinetic parameters during the study were maintained within the therapeutic window: trough level (C0) 132.2 ± 90.8 μg/L (therapeutic range of 75–150 μg/L for patients receiving long-term treatment); AUC(0–12) 3.4 ± 0.9hμg/mL (doseage AUC 3.8 hμg/mL); and maximal concentration (Cmax) 859.1 ± 253.0 μg/L. An EVR dose ranged from 2 to 5 mg/day, with target trough levels of 5 to 15 ng/mL. The characteristics of the study population are presented in Table 1. Protocol biopsies were performed and graded according to the Banff 97 classification.[29]

The study protocol was reviewed and approved by the Ethics Committee.

2.2. Determination of CsA

Blood samples were collected in EDTA tubes to measure the CsA C0 and drug-blood concentration 1 (C1) and 3 (C3) hours after the administration of CsA. CsA concentrations in the whole blood were measured using a validated turbulent-flow chromatography-tandem mass spectrometry technique.[30] Online extraction was performed at 1.25 mL/min on a Cyclone P, 50 μm particle size (50 × 0.5 mm, id) column (Thermo Fisher) in alkaline conditions. Chromatographic separation was performed in acidic conditions (phase A 0.1% formic acid in water and phase B 0.1% formic acid in methanol) using a Propel MS C18, 5 μm (50 × 30 mm, id) column (Thermo Fisher) kept at 60°C with a constant flow rate of 300 μL/min. Detection was performed using a TSQ Quantum Discovery tandem mass spectrometer equipped with an orthogonal electro spray ionization source and controlled by the XCalibur software (Thermo Fisher). Tandem mass spectrometry was performed in the positive ion multiple reaction monitoring (MRM) mode following 3 transitions for CsA (m/z 1220.0 → 1203.0 for quantitation and m/z 1220.0 → 1185.0 and m/z 1220.0 → 425.0 for confirmation) and 2 transitions (m/z 1234.0 → 1217.0 for quantitation and m/z 1234.0 → 119.0 for confirmation) for its analogue CsA D, used as an internal standard (IS). Methanol/aqueous zinc sulfate (200 μL, 70:30 v/v) containing the internal standard at 25 μg/L was added to the whole blood (100 μL). The mixture was vortexed for 45 seconds and centrifuged at 13,000 rpm, and the supernatant was introduced into a 200-μL vial for injection. Calibration standards at 0, 10, 20, 50, 100, 200, 500, 1000, and 2000 μg/L of CsA were prepared by spiking blank blood. The limits of detection (LOD) and quantification (LOQ) were 10 and 20 μg/L, respectively, and calibration curves obtained using quadratic regression from the LOQ to 20,000 μg/L yielded r2 > 0.999.

2.3. Determination of MPA

Blood samples were collected in EDTA tubes at 20 minutes, 1 and 3 hours after the administration of MMF. Plasma was separated by centrifugation. The measurement of total MPA was performed using a validated high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection.[31] Blood serum (500 μL), an internal standard (50 μL) (thiopental in methanol 1g/L diluted with deproteinized water to 25 mL/g), and calibrators were acidified with hydrochloric acid and extracted with dichloromethane (5 mL). Calibrators were prepared in drug-free plasma and their concentrations were 0, 0.5, 1, 5, 10, and 20 μg/L for MPA. The organic fraction was then evaporated to dryness under a stream of nitrogen. The dry residue was reconstituted with 100-μL elution solvent (KH2PO4 buffer/acetonic [70/30 v/v] at pH = 2.6). Then, the sample (40 μL) was injected into the HPLC system with a steel column Nucleosil C18, 5 μm (250 × 4.6 mm, id) and with UV detection at 300 nm. The limits of LOD analogue LOQ were 50 and 200 μg/L, respectively, and calibration curves obtained using quadratic regression from the LOQ to 20,000 μg/L yielded r2 > 0.999.

2.4. Pharmacokinetic analysis

The NONMEM version VI (GloboMax LLC) nonlinear mixed-effects population pharmacokinetic model and the Bayesian estimator of a 3-point limited sampling strategy developed at Limoges University Hospital were used to determine CsA[A22,33] and MPA[A31] area under the blood concentration–time curve (AUC(0–12)).

2.5. Statistical analysis

The values of MPA pharmacokinetic parameters (AUC(0–12) and Cmax) were compared between the patients’ groups receiving dual therapy with MMF and CsA (doses ranged from 120 to 300 mg/day), and between the patients of 3 treatment arms receiving MMF and CsA versus patients receiving MMF and EVR. IBM SPSS 20.0 was used for statistical analysis. Probability values of less than 0.05 were considered significant. Correlation coefficients were calculated using the Spearman and Pearson correlation tests. Brian P O’Connor Parallel Analysis (PA) to for determining the number of components to retain from principal components analysis (PCA) component was used on SPSS. PCA eigenvalues from the data greater than PA eigenvalues from the corresponding random data were retained. All components with eigenvalues below this threshold value were considered spurious.[35] The unpaired t test was used to compare the study groups (GraphPad software, available online: http://www.graphpad.com/quickcalcs/ttest1.cfm). The relationship between MPA AUC(0–12), CsA AUC(0–12), and dose was assessed with a linear regression analysis model.

3. Results

3.1. Analysis of CsA influence on MPA

A large interindividual variation of MPA pharmacokinetic data was observed with different MMF doses from 1000 to 3000 mg/day within each group (receiving dual therapy with MMF and CsA). A significant positive correlation within the MMF groups was noticed between the main MPA pharmacokinetic parameters (AUC(0–12) and Cmax). The patients treated with a higher CsA dose (180–240 mg/day) displayed higher MPA AUC(0–12) exposure than those who were treated with a low CsA dose (120–180 mg/day) in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 hμg/L; r2 = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.83 ± 11.08 hμg/L; r2 = 0.437, P < 0.01); and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 hμg/L; r2 = 0.608, P < 0.05).

The same positive correlation was also observed between a CsA dose and MPA Cmax. The patients treated with a high CsA dose (180–240 mg/day) had increased Cmax compared with the patients treated with a low CsA dose (120–180 mg/day) in the
low-dose MMF group (1000 mg/day) (22.83 ± 10.82 vs 12.08 ± 5.59 mg/L) and in the medium-dose MMF group (2000 mg/day) (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L). Spearman correlation coefficients were $r_s = 0.507$ ($P < 0.05$) and $r_s = 0.414$ ($P < 0.01$) in the low- (1000 mg/day) and medium-dose MMF groups, respectively. The comparison of pharmacokinetic parameters between the patients’ groups is demonstrated in Table 2.

For the full-scale data analysis linear regression was performed. Analysis showed that the AUC(0–12) of MPA was CsA dose dependent and accounted 15.0% of the cases ($r = 0.385$, $P < 0.01$) (Fig. 1). Moreover, weak dependency was noticed between the AUC(0–12) of MPA and CsA AUC(0–12), and this dependency explained only 8.6% of the cases ($r = 0.293$, $P < 0.01$) (Fig. 2). The AUC(0–12) of MPA dependency on CsA Cmax explained 5.4% of the cases ($r = 0.232$, $P < 0.05$) (Fig. 3).

MPA Cmax significantly correlated with a CsA dose ($r = 0.299$, $P < 0.01$) (Fig. 4), and MPA C0 significantly correlated with CsA AUC(0–12) ($r = 0.296$, $P < 0.01$). No correlation was observed between CsA C0 and MPA pharmacokinetic parameters, but an MMF dose significantly correlated with CsA C0 ($r = 0.221$, $P < 0.05$) (Fig. 5). Such drug-to-drug interaction and MPA AUC exposure dependency on CsA dose, CsA AUC, and CsA Cmax as well as MPA Cmax dependency on CsA dose and MPA C0 dependency on CsA AUC showed a strong relationship between CsA and MPA what might play a key role in individual therapy.

### 3.2. Use of parallel analysis

Parallel analysis was performed using 3 components and 5 variables: CsA dose, CsA C0, CsA AUC(0–12) exposure value, MPA C0, MPA AUC(0–12) exposure value. The results of the parallel analysis test showed that there was only 1 component to be retained for interpretation. A CsA dose should be retained and considered as the only 1 factor affecting the MMF AUC exposure.

### 3.3. Manifestation of chronic allograft nephropathy

In CsA co-administration groups, chronic allograft nephropathy (classification of MEDRA 18.0) was diagnosed in 36.8% of the

### Table 2
Comparison of pharmacokinetic parameters between the study groups.

| No | MMF dose, mg | CsA dose per day, mg | Patients, n, % | MPA AUC(0–12), mean ± SD, h mg/L | MPA Cmax mean ± SD, mg/L | MPA C0 mean ± SD, mg/L |
|----|--------------|---------------------|---------------|---------------------------------|------------------------|------------------------|
| 1  | 1000 mg CsA + MMF | 120–180 | 13 (68.4) | 28.08 ± 11.03 | 12.08 ± 5.59 | 0.62 ± 0.51 |
| 2  | 1000 mg CsA + MMF | 180–240 | 6 (31.6) | 40.50 ± 10.97 | 22.83 ± 10.82 | 0.50 ± 0.55 |
| 3  | 1000 mg CsA + MMF | 240–300 | 4 (28.6) | 36.20 ± 3.70 | 19.00 ± 5.39 | 1.20 ± 0.45 |
| 4  | 2000 mg CsA + MMF | 120–180 | 5 (35.7) | 43.40 ± 13.13 | 22.80 ± 8.12 | 1.20 ± 0.45 |
| 5  | 2000 mg CsA + MMF | 180–240 | 5 (35.7) | 43.40 ± 13.13 | 22.80 ± 8.12 | 1.20 ± 0.45 |
| 6  | 2000 mg CsA + MMF | 240–300 | 4 (28.6) | 56.75 ± 16.78 | 21.25 ± 8.77 | 1.50 ± 0.58 |
| 7  | 3000 mg CsA + MMF | 120–180 | 5 (35.7) | 43.40 ± 13.13 | 22.80 ± 8.12 | 1.20 ± 0.45 |
| 8  | 3000 mg CsA + MMF | 180–240 | 5 (35.7) | 43.40 ± 13.13 | 22.80 ± 8.12 | 1.20 ± 0.45 |
| 9  | 3000 mg CsA + MMF | 240–300 | 4 (28.6) | 56.75 ± 16.78 | 21.25 ± 8.77 | 1.50 ± 0.58 |

$C_0$ = trough level, CsA = cyclosporine, MMF = mycophenolate mofetil, MPA = mycophenolic acid, NS = not significant, SD = standard deviation.

*ANOVA test.*
patients in the low MMF dose group (7 of 19 patients), in 24.0% of the patients in the medium MMF dose group (12 of the 50 patients), and in 7.1% of the patients in the high MMF dose group (1 of the 14 patients). The presence of chronic allograft nephropathy did not correlate with MPA AUC exposure, but negatively correlated with MPA C₀ (\( r = -0.262, P = 0.017 \)) when MMF was co-administrated with CsA.

In EVR co-administration groups, chronic allograft nephropathy was diagnosed in 77.8% of the patients in the low MMF dose group (7 of the 9 patients), in 50.0% of the patients in the medium MMF dose group (2 of the 4 patients), and in 50.0% of the patients in the high MMF dose group (2 of the 4 patients). In total, chronic allograft nephropathy was diagnosed in 64.7% of the patients (11 of the 18 patients). There was a negative moderate correlation between the presence of chronic allograft nephropathy and MPA AUC exposure when MMF was co-administrated with EVR (\( r = -0.508, P = 0.037 \)).

3.4. Comparison of CsA and EVR effect on the main MPA pharmacokinetic parameters

The comparative analysis between 2 treatment arms (CsA + MMF vs EVR + MMF) showed a statistically significant difference in pharmacokinetic parameters. MPA C₀ and MPA AUC(0-12) were significantly lower in the CsA + MMF treatment arm compared with the EVR + MMF treatment arm (Tables 3 and 4). The greatest difference in the MPA C₀ and MPA AUC(0-12) between the CsA + MMF and EVR + MMF treatment arms was observed in the medium MMF dose (2000 mg) group (1.08 ± 0.34 vs 4.17 ± 0.78 mg/L and 38.74 ± 13.74 vs 68.69 ± 22.68 mg/L, respectively). In the patients’ group, where a medium MMF dose (2000 mg) was co-administered with EVR, the MPA AUC(0-12) was by 43% higher than in the patients’ group where a medium MMF dose (2000 mg) was co-administered with CsA.

4. Discussion

The results obtained in our study show the influence of CsA and EVR on the MPA plasma level. So far, the impact of sirolimus on the MPA plasma level has been investigated,[36,37] and MPA trough levels higher than expected have been documented by Cattaneo et al.[38] This is in agreement with the findings of our study where the MPA AUC was by 43% higher in the MMF + EVR than the MMF + CsA group.

Variation of MPA pharmacokinetic parameters between the study groups possibly is the evidence of CsA and MMF drug-to-drug interaction, which has been noticed by other studies as well.[15,39,40] Grinyo et al.[12] studied the influence of standard- and low-dose CsA on MPA exposure and found that CsA reduced the MPA exposure. It was documented by comparing CsA groups with low-dose tacrolimus or low-dose sirolimus groups. Filler and Feber[41] analyzed immunosuppressant interactions, including drug interactions between CsA and tacrolimus with MPA, in renal transplant children and concluded that different MMP doses were required with either CsA or tacrolimus to obtain the same results.

Several different mechanisms of drug interactions in order to explain the relation between MPA and CsA have been proposed.
by researchers, although the ultimate mechanism has not been elucidated yet. The most likely mechanism by which CsA reduces MPA enterohepatic recirculation is through inhibition of the multidrug resistance-associated protein 2 (MRP2) transporter; however, other, not yet identified, canalicular transporters might be implied.[42–44]

It is thought that CsA interacts with the enterohepatic cycling of MPA by inhibiting the MRP2.[45] MPAG biliary excretion decreases because of MRP2 inhibition caused by CsA. This leads to a diminution of MPA intestinal reabsorption (after deconjugation by the intestinal flora) and reduction in recirculation of MPA. MPAG displaces MPA from its protein binding sites, leading to an increased unbound fraction of MPA. If only the MPA–MPAG metabolic pathway is inhibited by CsA, an MPA increase must be linked to a decrease in MPAG.

The role of the MRP2 transporter in the hepatic disposition of MPA and MPAG has been studied widely in animal models.[42,43,45] Animal studies have demonstrated that CsA, but not tacrolimus, plays a role in inhibiting the biliary excretion of MPAG by the MRP2 transporter[42,45,46] and is the mechanism responsible for the interaction between CsA and MMF. Nevertheless, the clinical importance of the model approved on animals remains unanswered. Tetsuka et al.[47] have made it more complicated. They hypothesized that the sinusoidal efflux of MPA and/or MPAG was affected by CsA. In their study on sandwich-cultured hepatocytes, MPAG reduction by CsA was found. The authors identified that acyl-glucuronide, a minor MPA metabolite, did not change the biliary excretion index, which suggests that unique or additional transporter(s) are involved in biliary excretion of acyl-glucuronide. However, experimental evidence that CsA decreased the enterohepatic recirculation of MPA shortly after transplantation has been confirmed by Cattaneo et al in humans.[38] We also demonstrated this tendency despite dose lowering required for long-term treatment.

Table 3
Comparison of MMF pharmacokinetic parameters between CsA+MMF and EVR+MMF study groups.

| Parameter                  | CsA + MMF group | EVR + MMF group | P      |
|----------------------------|-----------------|-----------------|--------|
| No of patients             | 83              | 17              |        |
| MPA dose, mean ± SD (range), mg/day | 1399.76±631.48 (1000–3000) | 1705.88±848.88 (1000–3000) |        |
| MPA C0, mean ± SD (range), mg/L | 1.00±0.47 (0.00–2.00) | 2.58±1.43 (0.68–4.98) |        |
| MPA Cmax, mean ± SD (range), mg/L | 17.61±8.51 (0.00–41.00) | 14.34±6.38 (4.24–28.45) |        |
| MPA AUC(0–12 h), mean ± SD (range), h mg/L | 37.88±14.13 (10.00–79.00) | 47.05±21.90 (20.82–98.16) |        |

AUC = area under the concentration time curve, C0 = trough level, CsA = cyclosporine, EVR = everolimus, MMF = mycophenolate mofetil, MPA = mycophenolic acid, SD = standard deviation.

Table 4
Comparison of pharmacokinetic parameters between study subgroups.

| Group                        | No of patients | CsA group | EVR group | P      |
|------------------------------|----------------|-----------|-----------|--------|
| Low-dose MMF group, 1000 mg/day | 19             | 1.58±0.51 (0.00–1.00) | 1.61±0.65 (0.68–2.24) | 0.0001 |
| Medium-dose MMF group, 2000 mg/day | 50             | 15.47±8.93 (3.00–41.00) | 10.76±4.81 (4.24–19.85) | 0.1521 |
| High-dose MMF group, 3000 mg/day | 14             | 30.63±12.73 (10.00–54.00) | 31.89±8.43 (20.82–42.25) | 0.7898 |

AUC = area under the concentration time curve, CsA = cyclosporine, EVR = everolimus, MMF = mycophenolate mofetil, MPA = mycophenolic acid, SD = standard deviation.
this context, patients (high pumpers) treated with low doses of CsA would show lower drug exposure and this could affect MPA AUC exposure.\[17\,\[49\]

In addition, a significant difference in the MPA C_{\text{max}} suggests that the initial absorption of MMF is also CsA or MMF dose dependent (r_1 = 0.507, P < 0.05 and r_2 = 0.414, P < 0.01, respectively) (Table 2). These findings support the importance of therapeutic drug monitoring when designing combined immunosuppressive regimens.

In scientific discussion for the approval of CellCept, it has been noted that despite clearly defined data about the CsA effect on MPA levels, the interaction between CellCept and CsA has no clinical implication and current monitoring instructions are satisfactory.\[50\] Although this is a clear statement, researchers still insist that the use of a combination of drugs (CsA plus MMF) requires therapeutic drug monitoring and this study is not an exception. Better outcomes are achieved when therapeutic drug blood monitoring is performed.\[11\] In the present study, the MPA AUC was outside the therapeutic window range (range 30–60 h mg/L) in 34% of the study patients (31.3% in MMF+CsA vs 47.00% in MMF+EVR), and fewer cases of chronic allograft nephropathy were noted with a high MFP dose (3000 mg/day) (1.2% in MMF+CsA vs 11.8% in MMF+EVR). It was proved that each 1 mg/L increase in the MPA area under the plasma concentration (not exceeding AUC exposure range 30–60 h mg/L) versus time curve was associated with a 4% decreased risk of an event such as acute rejection, graft loss, or death (HR=0.96; 95% CI: 0.93–0.99). This means that the higher MPA AUC might not induce chronic allograft nephropathy and MMF dosing relatively safely can be increased if MMF is co-administrated with CsA in order to achieve the same MPA AUC.\[32\]

Prescription of CsA and MMF is still important while such CNI withdrawal therapies as EVR combination with MMF are more expensive\[53\] and not available in low-income countries. However, MMF+EVR therapy is more advanced than CsA+MMF therapy taking into account CsA-induced nephrotoxicity and other adverse effects.

5. Conclusions

The data of the present study suggest a possible CsA versus EVR influence on MMF pharmacokinetics. Study results show that CsA has an impact on the main MPA pharmacokinetic parameters (AUC_{0–12} and C_{\text{max}}) in a CsA dose-related manner, while EVR mildly influences or does not affect MPA pharmacokinetic parameters. Low-dose CsA (lower than 180 mg/day) reduces MPA AUC_{0–12} exposure under the therapeutic window and may lead to ineffective therapy, while a high-dose CsA (>240 mg/day) is related to greater than 10 mg/L MPA C_{\text{max}} and increases the likelihood of adverse events.

6. Limitations

This study involved a small number of patients, and more accurate data can be obtained in larger study groups. The high-dose MMF group included 14 patients: 5 early posttransplantation time patients versus 9 moderate posttransplantation time patients. The results of this group are limited. Moreover, all the study patients received glucocorticoid treatment in combination with MMF and CsA therapy according to hospital guidelines, but the influence of glucocorticoid use on the main MMF and CsA pharmacokinetic parameters was not evaluated.

Acknowledgments

The authors thank the Head of the Department of Pharmacology, Toxicology and Pharmacovigilance at the University Hospital of Limoges for giving us the opportunity to work in his Department. The authors also thank the staff of the Department for their hospitality and support.

References

[1] de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando) 2008;22:6–20.
[2] Clae CM, Mahalati K, Kibert BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002;2:789–95.
[3] Undre NA, van Hooff J, Christaas M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999;31:296–8.
[4] Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2005;354:1236–33.
[5] Davidson JA, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view. Diabetes Care 2004;27:805–12.
[6] Excellence NIfHaC. Immunosuppressive therapy for renal transplantation in adults. 2004; https://www.nice.org.uk/guidance/ta85. [Accessed January 25, 2017].
[7] Kidney Disease: Improving Global Outcomes Transplant Work Group-KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:3 (Suppl):81–53.
[8] Pohanka E. Conversion to everolimus in maintenance patients – current clinical strategies. Nephrol Dial Transplant 2006;21 (Suppl 3):ii24–9.
[9] Ruz JC, Campistol JM, Grinyo JM, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004;78:1312–8.
[10] Polanco N, Gonzalez Monte F, Folgueira MD, et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant Proc 2015;47:57–61.
[11] Deuse T, Bara C, Barton M, et al. A multi-center, randomized, open-label, parallel group phase IV trial investigating the outcome on renal function, efficacy and safety of CNI-reduction or elimination with everolimus in de novo heart transplant: recipients: the MANDELA study design. J Heart Lung Transplant 2015;34:S86.
[12] Grinyo JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004;78:1312–8.
[13] Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:541–58.
[14] Vrzal R, Zenata O, Bachleda P, et al. The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicol In Vitro 2015;29:1088–99.
[15] Picard N, Premaud A, Rousseau A, et al. A comparison of the effect of cyclosporin and sirolimus on the pharmacokinetics of mycophenolate mofetil in renal transplant patients. Br J Clin Pharmacol 2006;62:477–84.
[16] Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohemoptic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 2005;60:249–56.
[17] Llauio I, Cassis L, Torras J, et al. Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function. J Pharm Pharm Sci 2012;15:407–19.
[18] Franco A, Mas-Serrano P, Perez Contreras J, et al. Mammalian target of rapamycin inhibitor monotherapy: efficacy in renal transplantation. Transplant Proc 2015;47:364–7.
[19] Cicora F, Massari P, Acosta F, et al. Use of everolimus in renal transplant recipients: data from a national registry. Transplant Proc 2014;46:2991–5.
[20] Manza TM, Sforza D, Angelico R, et al. Everolimus and enterico-coated mycophenolate sodium ab initio after liver transplantation: midterm results. Transplant Proc 2012;44:1942–5.
Noreikaitė et al. Medicine (2017) 96:13

Conversion from everolimus with low-exposure cyclosporine to everolimus with myco-
phenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. Ann Transplant 2012;17:58–67.

Rivinius R, Helmschrott M, Ruhrparwar A, et al. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Des Dev Ther 2015;9:93–102.

Guba M, von Bretenbach P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128–35.

Stracke S, Ramudo L, Keller F, et al. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Transplant Proc 2006;38:766–70.

Trelinska J, Dachowska I, Baranska D, et al. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatr Blood Cancer 2016;00:1–7. DOI: 10.1002/pbc.26347.

Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial. J Clin Endocrinol Metab 2016;66c:2016255.

Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007;26:557–64.

Santoni M, Massari F, Cuscinu S. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cell Mol Immunol 2015;12:122–4.

Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713–23.

Picard N, Djebli N, Sauvage FL, et al. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 2007;35:350–5.

Na-Bangchang K, Supasyndh O, Supaporn T, et al. Simple and sensitive estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002;41:71–80.

Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004;43:253–66.

O’Connor BP. SPSS and SAS programs for determining the number of components using parallel analysis and velicer’s MAP test. Behav Res Methods Instrum Comput 2000;32:396–402.

Kreis H, Gisterne JM, Land W, et al. Stirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252–60.

Renders L, Steimbach R, Valerus T, et al. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 2004;27:181–5.

Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2003;5:2937–44.

Naito T, Shinno K, Maeda T, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull 2006;29:275–80.

de Winter BC, van Gelder T, Sombogaard F, et al. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 2009;36:541–64.

Filler G, Feber J. The transplanted child: new immunosuppressive agents and the need for pharmacokinetic monitoring. Paediatr Child Health 2002;7:525–32.

Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuro-
side possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmaco Exp Ther 2004;309:1029–35.

Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2003;3:987–94.

Westley IS, Brogan LR, Morris RG, et al. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 2006;34:261–6.

El-Sehik AA, Koenderink JB, Wouterse AC, et al. Renal glucuronida-
tion and multidrug resistance protein 2-/multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. Transl Res 2014;164:46–56.

Van Gelder T, Klupp J, Barton MJ, et al. Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enter-
olohepatic recirculation of MPA, thereby decreasing its exposure. J Heart Lung Transplant 2001;20:160–1.

Tetsuka K, Gerst N, Tamura K, et al. Glucuronidation and subsequent biliary excretion of mycophenolic acid in rat sandwich-cultured hepatocytes. Drug Metab Pharmacokinet 2014;29:129–34.

Kuypers DRJ. Immunotherapy in elderly transplant recipients. Drugs Aging 2009;26:713–37.

Llauró I, Colom H, Gimenez-Bonafe P, et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int 2013;26:177–86.

Agency EM Scientific discussion for the approval of CellCept: a Scientific discussion; 2004

Mohammadpour N, Elyasi S, Vahdati N, et al. A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci 2011;14:485–98.

Filler G, Lepage N, Delisle B, et al. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 2001;23:114–9.

Jürgensen JS, Arns W, Haš B. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach. Eur J Health Econ 2010;11:15–25.